BiologicsFinancialSports Medicine

An unmet need for knees: Biotech Histogenics sets terms for $60 million IPO

Keywords / Tickers: HSGX, XON
Related Links: Upcoming IPOs

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Check Also
Back to top button